Biogen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guida
Biogen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance above estimates. Also, Barclays raised its price target on the stock from $185 to $200.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.